检测方案
≥98% (HPLC)
形式
powder
储存条件
desiccated
颜色
white to beige
溶解性
DMSO: 2 mg/mL, clear (warmed)
储存温度
−20°C
SMILES字符串
[O-]P(O[C@H](CN(CC(C)C)S(C1=CC=C(N)C=C1)(=O)=O)[C@@H](NC(O[C@@H]2COCC2)=O)CC3=CC=CC=C3)([O-])=O.[Ca+2]
InChI
1S/C25H36N3O9PS.Ca/c1-18(2)15-28(39(33,34)22-10-8-20(26)9-11-22)16-24(37-38(30,31)32)23(14-19-6-4-3-5-7-19)27-25(29)36-21-12-13-35-17-21;/h3-11,18,21,23-24H,12-17,26H2,1-2H3,(H,27,29)(H2,30,31,32);/q;+2/p-2/t21-,23-,24+;/m0./s1
InChI key
PMDQGYMGQKTCSX-HQROKSDRSA-L
正在寻找类似产品? 访问 产品对比指南
生化/生理作用
Fosamprenavir calcium is an HIV protease inhibitor anti-retroviral. It is a water soluble phosphate ester prodrug of amprenavir, the active agent.
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Paola Nasta et al.
HIV clinical trials, 17(3), 96-108 (2016-04-30)
Safety and tolerability evaluation of adapted dose regimens containing fosamprenavir/ritonavir (FPV/r) in HIV-infected subjects with viral hepatitis co-infection. A retrospective multicohort analysis was conducted. Subjects from three European cohorts who started FPV/r or lopinavir/ritonavir (LPV/r) as a comparator contributed data
Lisa L Ross et al.
The open AIDS journal, 9, 38-44 (2015-07-15)
Treatment-emergent mutations and drug resistance were analyzed in virus from HIV-infected children meeting virologic failure (VF) criteria over 48 weeks following treatment with unboosted fosamprenavir or fosamprenavir/ritonavir-containing regimens in studies APV20002 and APV29005. Both antiretroviral therapy (ART)-naïve and ART-experienced patients
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门